Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

U937 treated with decitabine, panobinostat and valproic acid

ABSTRACT: U937 treated with decitabine, panobinostat and valproic acid

PROVIDER: PRJNA321257 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

U937 treated with decitabine, panobinostat and valproic acid [Illumina]

Project description:We employed the AML cell line model U937 to determine the effects of single and dual treatment with the HMA decitabine and the HDACi Pano or VPA on gene expression and DNA methylation. We noted global alterations of gene expression and a massive effect on the methylome.

2016-05-12 | GSE81308 | GEO

U937 treated with decitabine, panobinostat and valproic acid [Affymetrix]

2016-05-12 | GSE81307 | GEO

U937 treated with decitabine, panobinostat and valproic acid

Project description:This SuperSeries is composed of the SubSeries listed below.

2016-05-12 | GSE81309 | GEO

Homo sapiens

Project description:U937 treated with decitabine, panobinostat and valproic acid [Affymetrix]

| PRJNA321259 | ENA

Homo sapiens

Project description:U937 treated with decitabine, panobinostat and valproic acid [Illumina]

| PRJNA321258 | ENA

Transcription profiling of human embryonic stem cells in response to valproic acid and valproic acid analogs

Project description:Transcriptional profiling of valproic acid and valproic acid analogs in human embryonic stem cells.

2010-12-31 | E-MEXP-2374 | biostudies-arrayexpress

Identification differentially expressed genes upon valproic acid treatment

Project description:The goal of this study is to define genes that are differentially expressed in Down syndrome leukemic blasts after treatment with valproic acid (VPA) Here we report the identification gene sets that are downregulated in Down syndrome leukemic cell lines after exposure to valproic acid (VPA)

2011-07-13 | GSE30517 | GEO

Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer

Project description:The purpose of this study is to first determine the maximum tolerated dose of capecitabine given alone or in combination with valproic acid during preoperative short-course radiotherapy (Phase 1). The next part of the study (Phase 2)will explore whether the addition of valproic acid or the addition of capecitabine to short-course radiotherapy, before optimal radical surgery might increase the pathologic complete tumor regression rate in patients with low-moderate risk rectal cancer.

| 2148214 | ecrin-mdr-crc

Genome-wide expression profiling after Valproic acid treatment in Saccharomyces cerevisiae

Project description:Valproic acid (VA) is a small-chain branched fatty acid, widely used as anticonvulsant, and mood stabilizer to treat psychiatric illness. Valproic acid is also known to inhibit the histone deacetylases (HDACs), which makes it as a potent antitumor agent in alone or in combination with other cytotoxic drugs. Beside its conventional activities, valproic acid reported to have much broader, complicated effects and affect many complex physiological processes. However the molecular mechanisms of valproic acid are unclear. So, we used budding yeast transcriptome analysis to better understand the molecular mechanism of action of valproic acid. The clusters of differentially expressed genes in microarray after VA (6mM) treatment and their functional enrichment analysis revealed its overall effects on various biological processes such as cell cycle, signal transduction, metabolism, transcription, ubiquitination, transporter activities and many more. The microarray data were validated by quantitative real-time PCR.

2016-10-14 | GSE62400 | GEO

human placenta-derived cell line (JEG-3): Control vs. valproic acid(VPA)-treated

Project description:Transcriptional profiling of human placenta-derived JEG-3 cell line comparing vehicle control with 7.38 mM of valproic acid(VPA)-treated JEG-3 cells for 48 hr. 7.38 mM valproic acid(VPA) induced the 30% inhibiotion of JEG-3 cell proliferation, G1 phase cell cycle arrest and the reduction of cell size. The Goal was to analyze the mechanism of valproic acid-induced adverse effects in placental cells.

2012-10-11 | GSE41441 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data